1,721,136 research outputs found
Clinical challenges in the management of neuroendocrine tumors
Full text linkNeuroendocrine tumors (NET) are rare and heterogeneous diseases, whose prognosis is affected by several factors including the primary tumor site, grading, somatostatin receptor expression, and disease staging [...]
- Lineeguida AIOM-ITANET “Neoplasie Neuroendocrine gastroenteropancreatiche”; edizione 2015
No full text
Clinical relevance of the expression of somatostatin receptors in digestive endocrine tumours
No full text
Diagnostic work-up of digestive endocrine tumors [Work-up diagnostico nei tumori endocrini digestivi]
No full textDiagnostic approach to digestive endocrine tumors mainly depends on the site of the primary tumor. Endoscopy, together with endoscopic ultrasonography, plays a crucial role for diagnosis and treatment of both gastric and colorectal tumors. For pancreatic tumors, multislices helical CT, somatostatin receptor scintigraphy, together with MRI, bone scintigraphy and endoscopic ultrasound are usually required. Promising findings are emerging from the use of video-capsule endoscopy and position emission tomography to detect small bowel tumors. Histological evaluation of tumor tissue is crucial for the management of these tumors
Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis
No full textExocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia
No full textExocrine pancreatic insufficiency, which occurs in approximately 20% of the patients with GEP-NENs receiving SSAs octreotide and lanreotide, is an underestimated condition. The clinical picture of EPI in these patients may overlap with tumor-related symptoms and common direct SSAs’ side effects, such as diarrhea, abdominal pain, bloating, and flatulence.
Early recognition of EPI is mandatory since it may negatively affect patients’ quality of life, nutritional status, and long-term clinical outcomes
Gastrointestinal side effects of somatostatin analogs in neuroendocrine tumors: a focused review
No full textNeuroendocrine tumors (NETs) are a group of well-differentiated heterogeneous neoplasms characterized by slow progression and distinct clinical and biological behavior. In the majority of patients with NET, first-line treatment is represented by somatostatin analogs (SSAs) that, despite being drugs with high tolerability (even at high doses) and providing to carcinoid symptoms control and anti-proliferative effects, may present some side effects, with potential impact on quality of life and nutritional status. The most frequent side effects are represented by gastrointestinal events in particular alterations in bowel habits (diarrhea and constipation), abdominal pain, exocrine pancreatic insufficiency, and cholelithiasis. Considering the relative rarity of NETs, literature about frequency and standard clinical management of adverse events SSA-related is still lacking and heterogeneous. The aim of this review is to arm gastroenterologists and other physicians treating NET patients with essential knowledge on the side effects of SSAs. By identifying and managing these adverse events early, healthcare professionals can offer optimal care, avert foreseeable complications, and ensure the best outcomes for patients. Without such early recognition, there is a risk of diminishing the patient's quality of life and their ability to sustain treatment over time
- …
